Growth & profitability
- Revenue has declined 34.2% per year over the past 5 years.
Financial health
- Operating income covered interest expense -11.9× in the latest year.
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | — | -$984M | — | — | — | — | $4M |
| 2024 | — | -$1.1B | — | — | — | — | $864840 |
| 2023 | $37653 | -$21M | 0.0% | -55519.9% | — | — | $3M |
| 2022 | $131521 | -$14M | 0.0% | -10964.6% | -$15M | — | $11M |
| 2021 | $86987 | -$16M | 0.0% | -18130.3% | -$14M | — | $27M |
| 2020 | — | -$26M | — | — | — | — | $18M |
| 2019 | — | -$16M | — | — | -$13M | — | $18M |
| 2018 | — | -$10M | — | — | -$9M | — | $20M |
| 2017 | — | -$7M | — | — | — | — | $6M |
| 2016 | — | -$7M | — | — | -$7M | — | $4M |
| 2015 | — | -$12M | — | — | -$5M | — | $5M |
| 2014 | — | -$6M | — | — | — | — | $10M |
| 2013 | — | -$16M | — | — | — | — | $16M |
| 2012 | — | -$13M | — | — | -$5M | — | $10M |
| 2011 | — | -$8M | — | — | — | — | $171739 |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$2M | — | — | — | — | $6M |
| Dec '25 | — | -$2M | — | — | — | — | $4M |
| Sep '25 | — | -$3M | — | — | — | — | $11M |
| Jun '25 | — | -$2M | — | — | — | — | $2M |
| Mar '25 | — | -$2M | — | — | — | — | $3M |
| Dec '24 | — | -$3M | — | — | — | — | $864840 |
| Sep '24 | — | -$2M | — | — | — | — | $3M |
| Jun '24 | — | -$2M | — | — | — | — | $1M |
| Mar '24 | — | -$2M | — | — | — | — | $2M |
| Dec '23 | $0 | -$13M | — | — | — | — | $3M |
| Sep '23 | $7466 | -$2M | 0.0% | -28053.1% | — | — | $6M |
| Jun '23 | $13163 | -$3M | 0.0% | -23621.7% | — | — | $6M |
| Mar '23 | $17024 | -$3M | 0.0% | -17063.1% | — | — | $9M |
| Dec '22 | $0 | -$2M | — | — | -$2M | — | $11M |
| Sep '22 | $86047 | -$4M | 0.0% | -4540.0% | -$4M | — | $14M |
| Jun '22 | $30391 | -$4M | 0.0% | -11860.3% | -$3M | — | $18M |
| Mar '22 | $15083 | -$5M | 0.0% | -30565.1% | -$6M | — | $21M |
| Dec '21 | — | -$2M | — | — | -$3M | — | $27M |
| Sep '21 | — | -$4M | — | — | — | — | $30M |
| Jun '21 | — | -$4M | — | — | — | — | $35M |
How the market has priced OGEN against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, ORAGENICS INC's revenue has declined 34.2% per year. These are computed facts, not advice.
As of FY2025, ORAGENICS INC reported — of total debt against $4M of cash; operating income covered interest expense -11.9×.
In FY2025, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.